
Richard Moscicki, M.D. Dr. Moscicki serves as executive vice president, Science and Regulatory Advocacy and chief medical officer at PhRMA. He joined the organization in 2017 after serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served as the senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013.
Recent Posts
Continued R&D into Alzheimer’s disease means hope for patients, families and caregivers

Patient safety is at the heart of COVID-19 vaccine R&D

How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing

Fighting variants of COVID-19

Lessons learned from COVID-19: The way we develop new medicines is changing

Just released: PhRMA members’ new clinical trial diversity principles

Understanding the emergency use authorization process for COVID-19 vaccines

Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot

How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective

Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
